Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Murine autoantigen-specific type 1 regulatory T cells promote oligodendrogenesis through amphiregulin-EGFR signaling.

Science translational medicine·2026
Same author

Low-frequency bipolar versus high-frequency monopolar cortical and subcortical motor mapping in craniotomies for brain tumors.

Journal of neurosurgery·2026
Same author

Multi-dimensional decoding of the TSPO signal in animal models of neuroinflammation using fluorescence-conjugated DPA714.

Journal of neuroinflammation·2026
Same author

Failed resolution of inflammation in intracerebral haemorrhage.

Nature reviews. Neurology·2026
Same author

Myelin debris uptake by macrophages and microglia: Resolution of foam cells with a series of novel cyclodextrins.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same author

Metabolic Collapse in Acute CNS Injury: A Spatiotemporal Framework Linking Redox Failure, Ferroptosis, and Neurovascular Dysfunction.

Antioxidants & redox signaling·2026

Related Experiment Video

Updated: May 17, 2026

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Remyelination therapy for multiple sclerosis.

Michael B Keough1, V Wee Yong

  • 1Hotchkiss Brain Institute and the Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, T2N 4N1, Canada.

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|October 17, 2012
PubMed
Summary

Multiple sclerosis (MS) therapeutics currently target immune responses. New treatments aim to promote remyelination, the nervous system's repair mechanism, to restore function and prevent further damage.

More Related Videos

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Related Experiment Videos

Last Updated: May 17, 2026

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Area of Science:

  • Neuroscience
  • Immunology
  • Regenerative Medicine

Background:

  • Multiple sclerosis (MS) is a chronic central nervous system disease causing demyelination and axonal damage.
  • Current MS therapies focus on modulating the immune response to reduce disease activity.
  • Demyelinated axons are susceptible to irreversible damage, necessitating repair strategies.

Purpose of the Study:

  • To review the phenomenon of remyelination in MS.
  • To explore the potential of existing MS therapies in promoting remyelination.
  • To discuss novel therapeutic avenues for enhancing myelin repair in MS.

Main Methods:

  • Review of experimental models and clinical studies in MS patients.
  • Analysis of current MS medications for their remyelination potential.
  • Discussion of emerging therapeutic targets and strategies for remyelination.

Main Results:

  • Remyelination is an endogenous repair process crucial for restoring function in demyelinated axons.
  • While some MS therapies may have remyelination effects, specific pro-remyelination strategies are needed.
  • Inhibitory pathways in chronic MS lesions impede oligodendrocyte precursor cell differentiation and myelin formation.

Conclusions:

  • The next generation of MS therapeutics should combine immunomodulation with agents that promote myelin repair.
  • Enhancing remyelination holds promise for delaying disease progression and recovering neurological function in MS.
  • Targeting oligodendrocyte precursor cells and overcoming inhibitory pathways are key strategies for future MS treatments.